Clinical Trial Update: Rituximab Plus Cyclophosphamide in Treating Patients With Indolent Stage III or Stage IV Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Rituxan (Rituximab) plus Cytoxan (cyclophosphamide) for indolent stage III or stage IV non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Cytoxan (cyclophosphamide)
• Rituxan (rituximab)

Snippet

Sponsor: Hoag Memorial Hospital Presbyterian | Conditions: Lymphoma | Phase 2 | Status: WITHDRAWN